Aceso Plasma
Aceso Plasma develops investigational cold plasma medical devices focused on wound care, dermatology, and defense decontamination applications. Their flagship handheld device generates non-thermal, localized plasma from ambient air, supporting accelerated wound healing and reducing microbial and biofilm burden without increasing antimicrobial resistance. The technology has been validated in pre-clinical and investigational studies at multiple independent research institutes, including military and academic partners, and is currently advancing towards FDA clearance.
Industries
N/A
Products
A portable device that generates non-thermal plasma from ambient air, designed for reducing microbial and biofilm burden in wound care, dermatology, and equipment decontamination.
A chamber system for plasma-based high-level disinfection of sensitive equipment and surfaces, targeting MRSA, ESKAPE pathogens, and chemical agent neutralization.
A portable device that generates non-thermal plasma from ambient air, designed for reducing microbial and biofilm burden in wound care, dermatology, and equipment decontamination.
A chamber system for plasma-based high-level disinfection of sensitive equipment and surfaces, targeting MRSA, ESKAPE pathogens, and chemical agent neutralization.
Expertise Areas
- Wound care technology
- Antimicrobial plasma-based therapies
- Burn and chronic wound research
- Decontamination and CBRN applications
Key Technologies
- Cold plasma generation
- Reactive oxygen and nitrogen species (ROS/RNS) for antimicrobial action
- Handheld medical device engineering
- Animal model wound healing evaluation
Key People
Chief of Technology
Chief of Technology
News & Updates
Awarded a combined $1.55M in government SBIR funding to conduct pre-clinical research studies.
Pre-clinical studies completed across wound healing, antimicrobial efficacy, burn wound care, and chemical decontamination at five independent institutions.
Fulfilled $310,000 government order for device evaluation and field use.
Aceso Plasma Inc. Closes Initial Tranche of Series A Preferred Financing Led by Stony Lonesome Group
Aceso Plasma announces successful closure of a $500,000 Series A Preferred funding round to support advancement of cold plasma medical and decontamination technology.
Article describes cold plasma application for burn wound healing, showing bactericidal effects on pathogens and compatibility with wound recovery.
Closed initial tranche of Series A Preferred financing led by Stony Lonesome Group to support clinical development, regulatory advancement, and production development.
Awarded a combined $1.55M in government SBIR funding to conduct pre-clinical research studies.
Pre-clinical studies completed across wound healing, antimicrobial efficacy, burn wound care, and chemical decontamination at five independent institutions.
Fulfilled $310,000 government order for device evaluation and field use.
Aceso Plasma Inc. Closes Initial Tranche of Series A Preferred Financing Led by Stony Lonesome Group
Aceso Plasma announces successful closure of a $500,000 Series A Preferred funding round to support advancement of cold plasma medical and decontamination technology.
Article describes cold plasma application for burn wound healing, showing bactericidal effects on pathogens and compatibility with wound recovery.
Closed initial tranche of Series A Preferred financing led by Stony Lonesome Group to support clinical development, regulatory advancement, and production development.